19
Dec
2024

Vertex Pain Drug Fails, Puretech Delivers for IPF, Merck Dumps TIGIT, LAG3 Antibodies

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Lilly Buys In Vivo CAR-T, Psychedelics in the Fast Lane, Nektar Surges on Hair Loss Drug
RevMed Nails RAS, Lilly Acquires CrossBridge, & IPOs Line Up
Gilead’s Deal Streak, Neurocrine Grows, & Stipple & Sidewinder Megarounds
Lilly Buys Centessa, Takeda & Alumis Tyk2 Showdown, & Blackstone’s Megafund